STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

|  |  |  |
| --- | --- | --- |
| **More fuel to the fire: Some patients with non-celiac self-reported wheat sensitivity adaptive immunological responses in duodenal mucosa** |  | Recommendation |
| **Title and abstract**  Page 2. Line 34-36  Page 2. Line 41-46 | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found |
| Introduction | | |
| Background/rationale  Page 4. Line 89-96  Page 5. Line 97-119 | 2 | Explain the scientific background and rationale for the investigation being reported |
| Objectives  Page 5. 120-127 | 3 | State specific objectives, including any prespecified hypotheses |
| Methods | | |
| Study design  Page 7. Line 146 | 4 | Present key elements of study design early in the paper |
| Setting  Page 7. Line 147-150 | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| Participants  Page 7. Line 151-164  Page 7. Line 165-167  Page 8. Line 168-187 | 6 | (*a*) Give the eligibility criteria, and the sources and methods of selection of participants |
| Variables  “N/A” | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/ measurement  “N/A” | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias  “N/A” | 9 | Describe any efforts to address potential sources of bias |
| Study size  “N/A” | 10 | Explain how the study size was arrived at |
| Quantitative variables  Page 7. 165-167  Page 8. 168-187 | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods  Page.11. Line 255-262 | 12 | (*a*) Describe all statistical methods, including those used to control for confounding |
| (*b*) Describe any methods used to examine subgroups and interactions |
| (*c*) Explain how missing data were addressed |
| (*d*) If applicable, describe analytical methods taking account of sampling strategy |
| (*e*) Describe any sensitivity analyses |
| Results | | |
| Participants  Page 12. Line 267-275 | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
| (b) Give reasons for non-participation at each stage |
| (c) Consider use of a flow diagram |
| Descriptive data  Page 12. Line 267-275 | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
| (b) Indicate number of participants with missing data for each variable of interest |
| Outcome data  “N/A” | 15\* | Report numbers of outcome events or summary measures |
| Main results  Pages:12-14 | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
| (*b*) Report category boundaries when continuous variables were categorized |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |
| Other analyses  “N/A” | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |
| Discussion | | |
| Key results  Page 16-18 | 18 | Summarise key results with reference to study objectives |
| Limitations  Page 16. Line 354-361 | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation  Page 19. 928-437 | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results |
| Other information | | |
| Funding  Declarations form | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |

\*Give information separately for exposed and unexposed groups.